Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events

Yang Yang¹, Nianchun Peng¹, Gang Chen², Qin Wan³, Li Yan⁴, Guixia Wang⁵, Yingfen Qin⁶, Zuojie Luo⁶, Xulei Tang⁷, Yanan Hu⁸, Zhen Ye⁹, Guijun Qin¹⁰, Zhengnan Gao¹¹, Qing Su¹², Yiming Mu¹³, Jiajun Zhao¹⁴, Lulu Chen¹⁵, Lisiu Zeng¹⁵, Xuefeng Yu¹⁶, Qiang Li¹⁷, Feixia Shen¹⁸, Li Chen¹⁹, Yinfei Zhang²⁰, Youmin Wang²¹, Huacong Deng²², Chao Liu²³, Shengli Wu²⁴, Tao Yang²⁵, Mian Li²⁶,²⁷, Yu Xu²⁶,²⁷, Min Xu²⁶,²⁷, Zhiyun Zhao²⁶,²⁷, Tiange Wang²⁶,²⁷, Jieli Lu²⁶,²⁷, Yufang Bi²⁶,²⁷, Weiqing Wang²⁶,²⁷, Guang Ning²⁶,²⁷, Qiao Zhang¹,²⁸* and Lixin Shi¹,²⁸*

Abstract

Background: Whether smoking modifies the associations of diabetes and risk factor management with subsequent risk of cardiovascular disease (CVD), and whether the smoking related CVD risk differs among people with and without diabetes are unclear. This study aimed to examine the associations and interactions of smoking, diabetes, and risk factor management in relation to incident CVD.

Methods: This nationwide, population-based, prospective cohort study of 20 communities from various geographic regions recruited adults aged 40 years or older during 2011–2012. The follow-up survey was conducted between 2014 and 2016. This study included 126,181 participants who were free from CVD at baseline.

Results: Study participants included 19,397 current smokers (15.4%), 6,049 former smokers (4.8%), and 100,735 never smokers (79.8%). Mean (SD) age ranged from 55.8 (8.6) years to 60.7 (9.1) years. Compared with never smokers, heavy smokers exhibited a greater risk of CVD events among participants with diabetes (multivariable-adjusted hazard ratio [HR], 1.45; 95% CI, 1.17–1.78) than among participants without diabetes (HR, 1.20; 95% CI, 1.01–1.42; P for interaction = 0.006). Compared with participants without diabetes, participants with diabetes who were never smokers and had 5 or more controlled risk factors showed no significantly excess CVD risk (HR, 0.93; 95% CI, 0.71–1.22), but the cardiovascular benefits from risk factor management were counteracted among participants with diabetes who were current smokers (HR, 1.28; 95% CI, 0.77–2.14) or former smokers (HR, 1.22; 95% CI, 0.66–2.28).

Conclusions: Smoking and diabetes interacted with each other in relation to increased risk of CVD events, and the beneficial effect of risk factor management on CVD risk among participants with diabetes was attenuated by current or former smoking.

Keywords: Diabetes, Risk of cardiovascular disease, Smoking, Risk factor management

Introduction

Cigarette smoking is the leading preventable cause of morbidity and mortality worldwide, responsible for 11.5% (equivalent to 6.4 million) of global deaths annually [1, 2]. In China, smoking has been ranked as the
most important lifestyle risk factor contributing to deaths and disability-adjusted life-years [3]. Smoking substantially increases the risk of cardiovascular disease (CVD) in both the general population and patients with type 2 diabetes [4–6]. Compared with people without diabetes, patients with diabetes have a twofold additional hazard of CVD, occurring earlier and with greater severity [7–9]; meanwhile CVD remains the most common cause of mortality among patients with diabetes [10]. Therefore, interventions to prevent or quit smoking, together with cardiovascular risk factor management such as glycemic control and the management of blood pressure and cholesterol, are key recommendations for the prevention of CVD in diabetes [11, 12].

Smoking prevention and cessation interventions compare favorably with the management of other cardiovascular risk factors, in terms of both health improvements and cost savings [13]. However, a considerable proportion of people are likely to continue smoking even after a diagnosis of diabetes [14], and the successful rate of smoking cessation interventions for smokers with diabetes is not ideal [15]. Evaluating the interplay between cigarette smoking and diabetes status in relation to CVD risk is of the essence for prioritizing precise clinical and public health strategies to reduce the burden of CVD among patients with diabetes. Thus far, whether current smoking or smoking cessation modifies the associations of diabetes and risk factor management with the incidence of CVD, and whether the smoking-related CVD risk differs among people with and without diabetes are still unknown.

To fill this knowledge gap, we investigated the bidirectional interactions of active smoking and smoking cessation with diabetes status on subsequent risk of CVD events, and examined the association of cardiovascular risk factor management in diabetes with the risk of CVD across smoking status categories in a nationwide prospective cohort study.

Methods

Study participants

The China Cardiometabolic Disease and Cancer Cohort (4C) Study is a multicenter, population-based, prospective cohort study [16, 17]. The baseline survey was conducted between 2011 and 2012, and 19,3846 men and women aged 40 years or older were recruited from local resident registration systems of 20 communities from various geographic regions in China to represent the general population. The follow-up survey was conducted between 2014 and 2016; all participants were invited to attend an in-person visit, and 170,240 participants (87.8%) were followed up. The analysis included 126,181 participants who had complete baseline data on cigarette smoking, diabetes status, and covariates; were free from CVD at baseline; and had complete ascertainment of CVD events at the follow-up visit. This study was approved by the Medical Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University. All study participants provided written informed consent.

Data collection

Data collection was performed in local community clinics by trained study personnel according to standard protocols. Questionnaires comprising information on demographic characteristics, dietary and lifestyle factors, family history, and medical history were administered by trained interviewers. Education attainment was classified as less than high school (< 9 years) and high school or further education (≥ 9 years). A food frequency questionnaire was used to collect habitual dietary intake by asking the consumption frequency and portion size of typical food items during the previous 12 months. International Physical Activity Questionnaire was used to assess physical activity [18], and Metabolic equivalent (MET) was calculated to evaluate average weekly energy expenditure [19]. Physical activity was classified as active (≥ 600 MET-min/week), insufficiently active (> 0 to < 600 MET-min/week), and inactive (0 MET-min/week). Average alcohol consumption was calculated by multiplying amount of alcohol consumed per drinking day by frequency.

Height and body weight were measured according to a standard protocol, and body mass index (BMI) was calculated as body weight in kilograms divided by the square of height in meters.

Three measurements of systolic blood pressure (SBP) and diastolic blood pressure (DBP) were obtained by using an automated electronic device (OMRON Model HEM-752 FUZZY, Dalian, China) in a seated position after at least a 5-min quiet rest, and the 3 readings were averaged for analysis. Hypertension was defined as SBP ≥ 140 mmHg, or DBP ≥ 90 mmHg, or taking antihypertensive medication.

All participants underwent a 2-h, 75-g oral glucose tolerance test (OGTT) after an overnight fast of at least 10 h, and blood samples were collected at 0 and 2 h during the test. Fasting and 2-h plasma glucose concentrations were measured locally using a glucose oxidase or hexokinase method within 2 h after blood sample collection under a stringent quality control program. Fingertip capillary whole blood samples were collected by the Hemoglobin Capillary Collection System (Bio-Rad Laboratories, Hercules, CA, USA) and were shipped and stored at 2°C to 8°C until glycated hemoglobin A1c (HbA1c) was measured within 4 weeks after collection.
by high-performance liquid chromatography using the VARIANT II Hemoglobin Testing System (Bio-Rad Laboratories) at the central laboratory in the Shanghai Institute of Endocrine and Metabolic Diseases, which was certificated by the National Glycohemoglobin Standardization Program and the College of American Pathologists Laboratory Accreditation Program.

Serum low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, total cholesterol, and creatinine were measured at the central laboratory using an auto-analyzer (ARCHITECT ci16200, Abbott Laboratories, Chicago, IL, USA). Dyslipidemia was defined as LDL ≥ 160 mg/dL (4.14 mmol/L), or HDL < 40 mg/dL (1.04 mmol/L), or triglycerides ≥ 200 mg/dL (2.26 mmol/L), or total cholesterol ≥ 240 mg/dL (6.22 mmol/L), or taking lipid-lowering medications [20].

Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation [21]. Chronic kidney disease (CKD) was defined as eGFR < 60 mL/min/1.73 m² [2].

Assessment of cigarette smoking, diabetes, and risk factor management
Information on cigarette smoking was collected by a standard questionnaire. Current smokers were defined as participants who reported smoking cigarettes every day or almost every day, with at least 7 cigarettes per week for at least 6 months [2]. Intensity of current smoking was classified into light (<10 cigarettes per day), moderate (10-<20 cigarettes per day), and heavy (≥20 cigarettes per day) levels by number of cigarettes smoked [22]. Former smokers were defined as participants who reported not currently smoke cigarettes but had smoked at least 7 cigarettes per week for at least 6 months in a lifetime [2]. Former smokers were classified into short-term quitters (quit for <4 years), medium-term quitters (quit for 4-<8 years), and long-term quitters (quit for ≥8 years) by years since smoking cessation. Never smokers were defined as participants who reported never smoked or had not smoked cigarettes regularly (<100 cigarettes in a lifetime) [2]. Passive smoking was defined as exposure to 1 or more smokers during childhood or adulthood.

According to the American Diabetes Association 2010 criteria, diabetes was defined as: fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L), or OGTT 2-h plasma glucose ≥ 200 mg/dL (11.1 mmol/L), or HbA1c ≥ 6.5%, or a self-reported previous diagnosis of diabetes by health care professionals [23].

For participants with diabetes, we considered optimal management of 6 cardiovascular risk factors in accordance with previous studies: (1) fruits and vegetables intake ≥ 4.5 cup/day [24]; (2) physical activity ≥ 60 MET-min/week [24, 25]; (3) HbA1c < 6.5% [16, 26]; (4) SBP < 130 mmHg and DBP < 80 mmHg [27, 28]; (5) LDL cholesterol < 100 mg/dL [29]; (6) without CKD [29].

Ascertainment of cardiovascular events
The outcome was the composite of incident fatal or non-fatal CVD events, including cardiovascular death, myocardial infarction, stroke, and hospitalized or treated heart failure. The detailed definitions of CVD events have been described previously [16]. Deaths and clinical outcomes were collected from local vital registries of the National Disease Surveillance Point System and National Health Insurance System. Two members of the outcome adjudication committee independently verified each clinical event and assigned potential causes of death, and discrepancies were adjudicated by discussions involving other members of the committee. The members of the outcome adjudication committee were unaware of the baseline clinical characteristics of each participant.

Statistical analysis
Baseline characteristics of participants according to smoking status were summarized as means with standard deviations (SDs) for continuous variables and numbers with percentages for categorical variables. In the time-to-event analysis, participants were censored at the date of CVD diagnosis, death, or the end of follow-up, whichever occurred first. Person-time was calculated from the enrollment date to the censoring date for each participant. All participants had complete data of cigarette smoking, diabetes status, and covariates; missing data for risk factor variables were deleted from the analyses.

Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for CVD events associated with current smoking and smoking cessation among participants with and without diabetes, with adjustment for traditional CVD risk factors as well as baseline BMI, change in BMI during the follow-up period, and passive smoking. Associations of diabetes as well as elevated fasting glucose, elevated OGTT-2 h glucose, and elevated HbA1c with CVD events among current smokers, former smokers, and never smokers were also established. Multiplicative interactions between smoking and diabetes on CVD events were tested by including the product term (e.g., smoking status category × diabetes category) as well as smoking status and diabetes status in the models. We performed additional analyses to assess the associations and interactions between smoking and diabetes on non-fatal CVD events and CVD mortality. The numbers of
well-managed risk factors were summed for each participant to represent an overall management of all 6 risk factors. Associations of individual and overall cardiovascular risk factor management with CVD events among participants with diabetes according to smoking status, as compared with participants without diabetes were analyzed.

Statistical significance was assessed using a two-sided P value of < 0.05. Statistical analyses used SAS software, version 9.4 (SAS Institute Inc).

**Results**

Baseline characteristics of participants according to smoking status are shown in Table 1. Of the 126,181 participants, there were 19,397 current smokers (15.4%), 6,049 former smokers (4.8%), and 100,735 never smokers (79.8%). Compared with never smokers, current smokers or former smokers had higher proportions of men, were more likely to be exposed to passive smoking in childhood, and had lower proportions of family history of CVD. Current smokers consumed fewer fruits and vegetables, were less physically active, and had higher levels of alcohol consumption than former smokers or never smokers. Former smokers had poorer glucose profiles and higher blood pressures than current smokers or never smokers.

During 455,726 person-years (median, 3.2 years; interquartile range, 3.0–4.7 years) of follow-up, we documented 3,422 CVD events: 679 participants died from cardiovascular cause, 514 had myocardial infarction, 2,055 had stroke, and 251 had heart failure; participants may have experienced more than 1 CVD event. Compared with never smokers, current smokers had significantly higher hazard of CVD events among participants.

Table 1  Baseline characteristics of participants according to smoking status

| Characteristic                  | Current smokers | Former smokers | Never smokers |
|--------------------------------|-----------------|----------------|--------------|
|                                |    |                  | < 4 years     | 4–8 years    | ≥8 years     |
| Number of participants         | 19,397         | 2405           | 848          | 2796         | 100,735      |
| Age, year                      | 24.4 (4.3)     | 25.0 (3.5)     | 25.3 (3.5)   | 25.3 (3.6)   | 24.6 (3.6)   |
| Men, n (%)                     | 18,230 (94.0)  | 2247 (93.4)    | 800 (94.3)   | 2684 (96.0)  | 19,609 (19.5) |
| High school or further education, n (%) | 6761 (34.9) | 953 (39.6)     | 372 (43.9)   | 1237 (44.2)  | 36,787 (36.5) |
| Family history of diabetes, n (%) | 2310 (11.9) | 305 (12.7)     | 104 (12.3)   | 370 (13.2)   | 17,491 (17.4) |
| Family history of CVD, n (%)   | 2575 (13.3)    | 332 (13.8)     | 137 (16.2)   | 416 (14.9)   | 17,491 (17.4) |
| BMI, kg/m²                      | 24.4 (3.5)     | 25.0 (3.5)     | 25.3 (3.5)   | 25.3 (3.6)   | 24.6 (3.6)   |
| Passive smoking exposure in childhood, n (%) | 11,708 (60.4) | 1450 (60.3)    | 491 (57.9)   | 1642 (58.7)  | 45,019 (44.7) |
| Passive smoking exposure in adulthood, n (%) | 7536 (38.9) | 770 (32.0)     | 249 (29.4)   | 886 (31.7)   | 36,188 (35.9) |
| Fruits and vegetables intake, cup/day | 3.9 (3.6) | 4.2 (4.0)      | 4.7 (6.5)    | 5.2 (26.9)   | 4.2 (5.6)    |
| Physical activity, n (%)        |               |                |              |              |              |
| Active                         | 11,474 (59.2)  | 1609 (66.9)    | 607 (71.6)   | 2078 (74.3)  | 65,414 (64.9) |
| Insufficiently active          | 7425 (38.3)    | 734 (30.5)     | 224 (26.4)   | 671 (24.0)   | 32,590 (32.4) |
| Inactive                       | 498 (2.6)      | 62 (2.6)       | 17 (2.0)     | 47 (1.7)     | 2731 (2.7)   |
| Alcohol consumption, g/day     | 24.8 (45.1)    | 21.3 (44.6)    | 20.1 (40.7)  | 18.3 (36.2)  | 2.3 (13.7)   |
| Glucose profile                |               |                |              |              |              |
| Fasting glucose, mg/dL         | 108.6 (32.4)   | 112.0 (33.2)   | 114.4 (33.0) | 113.3 (34.2) | 106.6 (28.6) |
| OGTT-2 h glucose, mg/dL        | 143.9 (73.9)   | 154.7 (76.5)   | 164.5 (77.3) | 160.0 (78.6) | 147.8 (68.8) |
| HbA1c, %                       | 6.0 (1.1)      | 6.1 (1.2)      | 6.2 (1.2)    | 6.2 (1.1)    | 6.0 (1.0)    |
| Blood pressure                 |               |                |              |              |              |
| SBP, mm Hg                     | 132.9 (20.0)   | 136.3 (20.3)   | 136.9 (18.7) | 136.7 (20.0) | 132.6 (20.9) |
| DBP, mm Hg                     | 798 (11.5)     | 80.7 (11.3)    | 81.6 (11.2)  | 80.8 (11.2)  | 78.0 (11.0)  |
| Lipid profile                  |               |                |              |              |              |
| LDL cholesterol, mg/dL         | 108.1 (32.3)   | 108.4 (33.1)   | 105.7 (33.3) | 108.5 (33.6) | 112.2 (34.2) |
| HDL cholesterol, mg/dL         | 49.3 (13.0)    | 48.3 (14.1)    | 47.5 (14.7)  | 47.6 (13.1)  | 52.5 (13.8)  |
| Triglycerides, mg/dL           | 158.6 (132.8)  | 154.4 (120.5)  | 157.9 (130.4)| 148.5 (109.3)| 142.0 (103.4)|
| Total cholesterol, mg/dL       | 187.3 (42.2)   | 186.4 (44.0)   | 182.6 (43.4) | 185.0 (44.1) | 193.5 (44.2) |
| eGFR, mL/min/1.73m²            | 95.6 (13.2)    | 92.7 (14.3)    | 91.1 (14.9)  | 89.8 (15.2)  | 93.6 (13.4)  |

Values are mean (SD) for continuous variables and number (proportion) for categorical variables. Overall, the numbers of missing values are 120 for fasting glucose, 683 for OGTT-2 h glucose, 179 for HbA1c, 666 for SBP, 673 for DBP, 276 for LDL cholesterol, 278 for HDL cholesterol, 380 for triglycerides, 259 for total cholesterol, and 297 for eGFR. Percentages may not sum to 100% due to rounding.
with diabetes (HR, 1.29; 95% CI, 1.08–1.54) than among participants without diabetes (HR, 1.24; 95% CI, 1.09–1.43; P for interaction = 0.034; Table 2). A significant interaction between current smoking intensity and diabetes on CVD events was also identified: the HRs for comparison of heavy smokers with never smokers were 1.45 (95% CI, 1.17–1.78) among participants with diabetes and 1.20 (95% CI, 1.01–1.42) among participants without diabetes (P for interaction = 0.006; Fig. 1A). A graded inverse association between years since smoking cessation and CVD events was observed: the HRs as compared with current smokers were 1.14 (95% CI, 0.83–1.56) for short-term quitters and 0.78 (95% CI, 0.57–1.06) for long-term quitters among participants with diabetes, and were 1.10 (95% CI, 0.84–1.43) for short-term quitters and 0.63 (95% CI, 0.46–0.85) for long-term quitters among participants without diabetes (P for interaction = 0.86; Fig. 1B). We observed similar associations of current smoking and smoking cessation with fatal and non-fatal CVD events, separately (Additional file 1: Figures S1, S2).

Diabetes as well as elevated fasting glucose, elevated OGTT-2 h glucose, and elevated HbA1c were associated with increased hazards of CVD events, and these associations were more prominent among current smokers and former smokers than among never smokers (Table 3). The multivariable-adjusted HRs for CVD events associated with diabetes were 1.61 (95% CI, 1.36–1.91) among current smokers, 1.70 (95% CI, 1.31–2.22) among former smokers, and 1.37 (95% CI, 1.26–1.49) among never smokers (P for interaction = 0.034). Significant interaction was also observed for elevated HbA1c (P for interaction = 0.011), whereas no statistically significant interaction was observed for elevated fasting glucose or elevated OGTT-2 h glucose. Similar but weaker results were observed for fatal and non-fatal CVD events separately (Additional file 1: Table S1).

Compared with participants without diabetes, participants with diabetes who had each individual controlled risk factor showed relatively lower hazards of CVD events among never smokers than among current or former smokers (Fig. 2A). Compared with participants without diabetes, participants with diabetes who had 5 or more controlled risk factors exhibited no significantly excess risk for CVD events (HR, 1.02; 95% CI, 0.81–1.27; Table 4). Such favorable effect of 5 or more controlled risk factors on CVD risk was more prominent among never smokers (HR, 0.93; 95% CI, 0.71–1.22), but was offset among current smokers (HR, 1.28; 95% CI, 0.77–2.14) or former smokers (HR, 1.22; 95% CI, 0.66–2.28; Fig. 2B).

### Discussion

In this nationwide prospective cohort study in China, we have provided novel and quantitative data about the interplay of cigarette smoking with diabetes and cardiovascular risk factor management on subsequent risk of CVD events. Compared with adults without diabetes, adults with diabetes were more susceptible to the

| Category | No. of participants | Person-years | Cases | HR (95% CI) | Further adjusted for baseline BMI, and BMI change | Further adjusted for passive smoking |
| --- | --- | --- | --- | --- | --- | --- |
| | Adjusted for CVD risk factors | | | | | |
| Diabetes | | | | | | |
| Never smokers | 22,764 | 81,515 | 943 | 1.00 [Ref.] | 1.00 [Ref.] | 1.00 [Ref.] |
| Former smokers | 1913 | 6889 | 112 | 1.15 (0.92–1.43) | 1.15 (0.92–1.43) | 1.15 (0.93–1.43) |
| Current smokers | 4523 | 16,226 | 233 | 1.29 (1.08–1.54) | 1.29 (1.08–1.53) | 1.29 (1.08–1.54) |
| No diabetes | | | | | | |
| Never smokers | 77,971 | 281,612 | 1604 | 1.00 [Ref.] | 1.00 [Ref.] | 1.00 [Ref.] |
| Former smokers | 4136 | 15,002 | 128 | 1.07 (0.88–1.30) | 1.06 (0.88–1.30) | 1.07 (0.88–1.30) |
| Current smokers | 14,874 | 54,483 | 402 | 1.23 (1.07–1.41) | 1.24 (1.08–1.42) | 1.24 (1.09–1.43) |

126,181 participants were included in the analysis

* Adjusted for age, sex, education attainment (less than high school, high school or further education), family history of diabetes (yes, no), family history of CVD (yes, no), fruits and vegetables intake (<4.5 cup/day, ≥4.5 cup/day), physical activity (active, insufficiently active, inactive), alcohol consumption, hypertension (yes, no), and dyslipidemia (yes, no)

* Adjusted for CVD risk factors as listed above, as well as baseline BMI, BMI change during follow-up, and passive smoking exposure in childhood and adulthood

* Interaction of diabetes with smoking status in relation to CVD events was adjusted for CVD risk factors as listed above, as well as baseline BMI, BMI change during follow-up, and passive smoking exposure in childhood and adulthood
deleterious effect of current smoking, especially heavy smoking, on CVD events. From another perspective, the excess CVD risks associated with diabetes and elevated glycemic traits were exacerbated among current smokers and former smokers, and the beneficial effect of risk factor management on CVD events among adults with diabetes seemed to be substantially attenuated by current or former smoking.

Our findings support a bidirectional interaction between smoking and diabetes on incident CVD events. Cigarette smoking and diabetes contribute independently to increased risk of CVD [4–8], and among people with diabetes, smoking is the key lifestyle risk factor for CVD [6]. In addition, current smokers have longer duration of exposure to passive smoking than never smokers and passive smoking is associated with an increased risk of CVD [30–32]. Given the considerable prevalence of smoking and the relatively low smoking cessation rate among people with diabetes and the effects of passive smoking on aspects of human health [14, 15], the specific effect that smoking poses to the diabetes population deserves special attention, and exposure to secondhand smoke should be minimized or avoided in order to reduce public health hazards [6, 33]. Prospective studies investigating the interaction between smoking and diabetes on CVD events are scarce and have revealed no evidence that the smoking-related CVD risk is greater in people with diabetes than in those without diabetes [34, 35]. In this study, taking advantage of a large nationwide sample with detailed records of smoking behaviors and comprehensive glycemic measurements, we extended previous evidence by showing that smoking and diabetes could amplify the deleterious effect of each other on subsequent risk of CVD, and the interaction between smoking and diabetes was quite consistent when diagnosing diabetes by each of the glycemic traits, especially elevated HbA1c. Our findings thus underline the importance of avoiding or quitting smoking for the effective prevention of CVD events, particularly for people with diabetes.

Our results also support a noteworthy conclusion that the favorable effects of optimal management of cardiovascular risk factors on incident CVD events among adults with diabetes could be considerably counteracted by smoking. Previous studies have demonstrated that substantial additional reductions in major CVD events in adults with diabetes can be achieved through ideal control of cardiovascular risk factors [16, 36–38]. In this study, the favorable cardiovascular effect of an ideal control of 5 or more risk factors in diabetes was only seen in never smokers; the CVD risk remained high among adults with diabetes who were current smokers or former smokers, even with optimal risk factor management. These results suggest that smoking is an important barrier for people with diabetes to gain cardiovascular benefits through risk factor management.

The precise mechanisms to explain our observations are unclear. Theoretically, both smoking and diabetes contribute to the development of cardiac dysfunction via promoting oxidative stress, inducing endothelial injury,
Table 3  Association of diabetes, elevated fasting glucose, elevated OGTT-2 h glucose, and elevated HbA1c with CVD events among current, former, and never smokers

| Category                  | No. of participants | Person-years | Cases | HR (95% CI) | Further adjusted for CVD risk factors a | Further adjusted for baseline BMI, and BMI change | Further adjusted for passive smoking b | P for interaction |
|---------------------------|---------------------|--------------|-------|-------------|-----------------------------------------|------------------------------------------------|---------------------------------------|------------------|
|                           |                     |              |       |             | Adjusted for CVD risk factors a         |                                                 | Further adjusted for passive smoking b |                  |
| Diabetes                  |                     |              |       |             |                                         |                                                 |                                       | 0.034            |
| Current smokers           |                     |              |       |             |                                         |                                                 |                                       |                  |
| No diabetes               | 14,874              | 54,483       | 402   | 1.00 [Ref] | 1.00 [Ref]                             | 1.00 [Ref]                                     |                                       |                  |
| Diabetes                  | 4523                | 16,226       | 233   | 1.60 (1.35–1.89) | 1.61 (1.36–1.91) | 1.61 (1.36–1.91)                      |                                        |                  |
| Former smokers            |                     |              |       |             |                                         |                                                 |                                       |                  |
| No diabetes               | 4136                | 15,002       | 128   | 1.00 [Ref] | 1.00 [Ref]                             | 1.00 [Ref]                                     |                                       |                  |
| Diabetes                  | 1913                | 6889         | 112   | 1.67 (1.28–2.16) | 1.71 (1.31–2.22) | 1.70 (1.31–2.22)                      |                                        |                  |
| Never smokers             |                     |              |       |             |                                         |                                                 |                                       |                  |
| No diabetes               | 77,971              | 281,612      | 1604  | 1.00 [Ref] | 1.00 [Ref]                             | 1.00 [Ref]                                     |                                       |                  |
| Diabetes                  | 22,764              | 81,515       | 943   | 1.38 (1.27–1.50) | 1.37 (1.26–1.49) | 1.37 (1.26–1.49)                      |                                        |                  |
| Elevat ed fasting glucose |                     |              |       |             |                                         |                                                 |                                       | 0.11             |
| Current smokers           |                     |              |       |             |                                         |                                                 |                                       |                  |
| Fasting glucose < 126 mg/dL | 16,722             | 61,110       | 484   | 1.00 [Ref] | 1.00 [Ref]                             | 1.00 [Ref]                                     |                                       |                  |
| Fasting glucose ≥ 126 mg/dL | 2653               | 9522         | 147   | 1.69 (1.40–2.05) | 1.71 (1.41–2.07) | 1.71 (1.41–2.07)                      |                                        |                  |
| Former smokers            |                     |              |       |             |                                         |                                                 |                                       |                  |
| Fasting glucose < 126 mg/dL | 4931               | 17,868       | 172   | 1.00 [Ref] | 1.00 [Ref]                             | 1.00 [Ref]                                     |                                       |                  |
| Fasting glucose ≥ 126 mg/dL | 1110               | 3997         | 68    | 1.61 (1.21–2.15) | 1.66 (1.24–2.22) | 1.66 (1.24–2.22)                      |                                        |                  |
| Never smokers             |                     |              |       |             |                                         |                                                 |                                       |                  |
| Fasting glucose < 126 mg/dL | 89,021             | 321,598      | 2011  | 1.00 [Ref] | 1.00 [Ref]                             | 1.00 [Ref]                                     |                                       |                  |
| Fasting glucose ≥ 126 mg/dL | 11,624             | 41,208       | 532   | 1.47 (1.34–1.63) | 1.46 (1.33–1.61) | 1.46 (1.33–1.61)                      |                                        |                  |
| Elevated OGTT-2 h glucose |                     |              |       |             |                                         |                                                 |                                       | 0.28             |
| Current smokers           |                     |              |       |             |                                         |                                                 |                                       |                  |
| OGTT-2 h glucose < 200 mg/dL | 16,273             | 59,462       | 464   | 1.00 [Ref] | 1.00 [Ref]                             | 1.00 [Ref]                                     |                                       |                  |
| OGTT-2 h glucose ≥ 200 mg/dL | 3035              | 10,918       | 163   | 1.56 (1.30–1.88) | 1.57 (1.31–1.90) | 1.57 (1.31–1.90)                      |                                        |                  |
| Former smokers            |                     |              |       |             |                                         |                                                 |                                       |                  |
| OGTT-2 h glucose < 200 mg/dL | 4697               | 16,999       | 160   | 1.00 [Ref] | 1.00 [Ref]                             | 1.00 [Ref]                                     |                                       |                  |
| OGTT-2 h glucose ≥ 200 mg/dL | 1282              | 4646         | 75    | 1.44 (1.09–1.91) | 1.45 (1.10–1.93) | 1.45 (1.10–1.93)                      |                                        |                  |
| Never smokers             |                     |              |       |             |                                         |                                                 |                                       |                  |
| OGTT-2 h glucose < 200 mg/dL | 85,342             | 307,942      | 1844  | 1.00 [Ref] | 1.00 [Ref]                             | 1.00 [Ref]                                     |                                       |                  |
| OGTT-2 h glucose ≥ 200 mg/dL | 14,869             | 53,371       | 684   | 1.44 (1.32–1.58) | 1.43 (1.31–1.57) | 1.44 (1.31–1.58)                      |                                        |                  |
| Elevated HbA1c            |                     |              |       |             |                                         |                                                 |                                       | 0.011            |
Table 3 (continued)

| Category          | No. of participants | Person-years | Cases | HR (95% CI) | Further adjusted for baseline BMI, and BMI change | Further adjusted for passive smoking |
|-------------------|---------------------|--------------|-------|-------------|--------------------------------------------------|-------------------------------------|
|                   |                     |              |       | Adjusted for CVD risk factors | P for interaction |
| Current smokers   |                     |              |       | Adjusted for CVD risk factors | P for interaction |
| HbA1c < 6.5%      | 16,402              | 59,910       | 467   | 1.00 [Ref]  | 1.00 [Ref]                                      | 1.00 [Ref] |
| HbA1c ≥ 6.5%      | 2955                | 10,652       | 167   | 1.69 (1.41–2.04) | 1.72 (1.42–2.07) | 1.72 (1.43–2.07) |
| Former smokers    |                     |              |       | Adjusted for CVD risk factors | P for interaction |
| HbA1c < 6.5%      | 4800                | 17,404       | 159   | 1.00 [Ref]  | 1.00 [Ref]                                      | 1.00 [Ref] |
| HbA1c ≥ 6.5%      | 1237                | 4446         | 78    | 1.77 (1.34–2.34) | 1.83 (1.38–2.43) | 1.83 (1.38–2.43) |
| Never smokers     |                     |              |       | Adjusted for CVD risk factors | P for interaction |
| HbA1c < 6.5%      | 85,759              | 309,451      | 1899  | 1.00 [Ref]  | 1.00 [Ref]                                      | 1.00 [Ref] |
| HbA1c ≥ 6.5%      | 14,849              | 53,219       | 643   | 1.39 (1.27–1.52) | 1.38 (1.25–1.51) | 1.37 (1.25–1.51) |

126,181 participants were included in the analysis. The numbers of missing values are 120 for fasting glucose, 683 for OGTT-2 h glucose, and 179 for HbA1c.

b Adjusted for age, sex, education attainment (less than high school, high school or further education), family history of diabetes (yes, no), family history of CVD (yes, no), fruits and vegetables intake (< 4.5 cup/day, ≥ 4.5 cup/day), physical activity (active, insufficiently active, inactive), alcohol consumption, hypertension (yes, no), and dyslipidemia (yes, no).

c Interactions of diabetes, elevated fasting glucose, elevated OGTT-2 h glucose, and elevated HbA1c with smoking status in relation to CVD events were adjusted for CVD risk factors as listed above, as well as baseline BMI, BMI change during follow-up, and passive smoking exposure in childhood and adulthood.

Table 4  Association of cardiovascular risk factor management with CVD events among participants with diabetes, as compared with participants without diabetes

| Category                              | Person-years | Cases | HR (95% CI) |
|---------------------------------------|--------------|-------|-------------|
| No diabetes                           | 351,096      | 2134  | 1.00 [Ref]  |
| Diabetes                              |              |       |             |
| Individual cardiovascular risk factor management | |       |             |
| Optimal fruits and vegetables intake  | 44,791       | 485   | 1.33 (1.20–1.47) |
| Optimal physical activity             | 71,765       | 898   | 1.43 (1.32–1.55) |
| HbA1c < 6.5%                          | 35,669       | 391   | 1.27 (1.14–1.42) |
| SBP/DBP < 130/80 mmHg                 | 29,104       | 221   | 1.12 (0.97–1.28) |
| LDL cholesterol < 100 mg/dL           | 37,126       | 397   | 1.28 (1.15–1.43) |
| No CKD                                | 100,376      | 1154  | 1.39 (1.29–1.50) |
| Overall cardiovascular risk factor management | |       |             |
| 2 or fewer controlled risk factors    | 34,699       | 542   | 1.79 (1.62–1.97) |
| 3 controlled risk factors             | 34,582       | 428   | 1.50 (1.35–1.67) |
| 4 controlled risk factors             | 24,629       | 238   | 1.25 (1.09–1.43) |
| 5 or more controlled risk factors     | 10,720       | 80    | 1.02 (0.81–1.27) |

Number of participants included in the analysis of individual risk factor management: 96,981 without diabetes, 12,408 with diabetes and fruits and vegetables intake ≥ 4.5 cup/day, 19,921 with diabetes and physical activity ≥ 600 MET-min/week; 9,980 with diabetes and HbA1c < 6.5%, 8,052 with diabetes and SBP/DBP < 130/80 mmHg, 10,312 with diabetes and LDL cholesterol < 100 mg/dL, and 28,032 with diabetes and no CKD. Number of participants included in the analysis of overall risk factor management: 96,981 without diabetes, 9,973 with diabetes and ≤ 2 controlled risk factors, 9,667 with diabetes and 3 controlled risk factors, 8,646 with diabetes and 4 controlled risk factors, and 2,934 with diabetes and ≥ 5 controlled risk factors.

* For analysis of individual risk factor management: adjusted for age, sex, education attainment (less than high school, high school or further education), family history of diabetes (yes, no), family history of CVD (yes, no), fruits and vegetables intake (< 4.5 cup/day, ≥ 4.5 cup/day; not for fruits and vegetables intake analysis), physical activity (active, insufficiently active, inactive; not for physical activity analysis), alcohol consumption, hypertension (yes, no; not for SBP/DBP analysis), dyslipidemia (yes, no; not for LDL cholesterol analysis), baseline BMI, BMI change during follow-up, active smoking (never smoker, former smoker, current smoker), and passive smoking exposure in childhood and adulthood. For analysis of overall risk factor management: adjusted for age, sex, education attainment (less than high school, high school or further education), family history of diabetes (yes, no), family history of CVD (yes, no), alcohol consumption, baseline BMI, BMI change during follow-up, active smoking (never, former, current smoking), and passive smoking exposure in childhood and adulthood.
and leading formation of atheroma [39], and these shared pathogenic pathways may underlie the interplay between smoking and diabetes on CVD. In addition, smoking is independently associated with the devastating cardiovascular health consequences for people with diabetes [39, 40]. Therefore, the benefits of ideal management of other risk factors may not fully outweigh the smoking-related cardiovascular risk. Experimental studies are needed to shed light on potential mechanisms responsible for the interplay between smoking and diabetes on CVD risk.

The strengths of this study included the large nationwide sample size, the prospective study design, the detailed records of smoking behaviors and comprehensive measurements of glycemic traits, and the well-validated definitions of the CVD outcomes. This study also has several limitations. First, the self-reported nature of smoking information may underestimate the prevalence of smoking as ascertained by cotinine measurement, and biochemical verification is needed to confirm the findings of this study. Second, we could not fully consider the residual and unmeasured confounders, such as the use of aspirin and metformin, which has been suggested to help prevent CVD risk in certain patients [41]. Third, the large sample size of this study can enhance the reliability of our findings and has advantages in permitting stratified analyses. However, because of the large sample size in this study, a statistically significant finding might not necessarily be clinically significant; thus, significant findings derived from this study must be analyzed and interpreted with caution. Fourth, similar to previous National Smoking Survey [42] and China Noncommunicable Disease Surveillance [43], the proportion of smokers were extremely low in Chinese women. Therefore, the limited number of smokers restricted the statistical power to perform sex-stratification analysis in this study. Fifth, the participants were middle-aged and elderly Chinese
adults, and a majority of current smokers and former smokers were men. Thus, the generalizability of our findings to other groups should be cautious.

Conclusions
Smoking and diabetes significantly interacted with each other in imposing increased risks of subsequent CVD events, and the cardiovascular benefits of risk factor management in diabetes could be counteracted by former or current smoking. Our findings highlight the particular importance of avoiding or quitting smoking to reduce the preventable burden of CVD in people with diabetes.

Abbreviations
CKD: Chronic kidney disease; CVD: Cardiovascular disease; DBP: Diastolic blood pressure; eGFR: Estimated glomerular filtration rate; HbA1c: Hemoglobin A1c; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; MET: Metabolic equivalent; OGTT: Oral glucose tolerance test; SBP: Systolic blood pressure.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933-022-01447-2.

Additional file 1: Table S1. Association of diabetes, elevated fasting glucose, elevated OGTT-2h glucose, and elevated HbA1c with non-fatal CVD events and CVD mortality among current, former, and never smokers. 126,181 participants were included in the analysis. The numbers of missing values are 120 for fasting glucose, 683 for OGTT-2h glucose, and 179 for HbA1c. Adjusted for age, sex, education attainment (less than high school, high school or further education), family history of diabetes (yes, no), family history of CVD (yes, no), fruits and vegetables intake (<4.5 cup/day, ≥4.5 cup/day), physical activity (active, insufficiently active, inactive), alcohol consumption, hypertension (yes, no), dyslipidemia (yes, no), baseline BMI, BMI change during follow-up, and passive smoking exposure in childhood and adulthood. Person-years for CVD mortality was longer than that for non-fatal CVD events, because participants may have experienced more than one CVD event. Figure S1. Association of current smoking with non-fatal CVD events and CVD mortality among participants with and without diabetes. Number of participants included in the analysis: 19,397 current smokers and 100,735 never smokers. Light smokers (n=3,020) referred to participants who smoked <10 cigarettes per day, moderate smokers (n=5,051) referred to participants who smoked 10–20 cigarettes per day, and heavy smokers (n=11,326) referred to participants who smoked ≥20 cigarettes per day. HRs (95% CIs) and P value were adjusted for age, sex, education attainment (less than high school, high school or further education), family history of diabetes (yes, no), family history of CVD (yes, no), fruits and vegetables intake (<4.5 cup/day, ≥4.5 cup/day), physical activity (active, insufficiently active, inactive), alcohol consumption, hypertension (yes, no), dyslipidemia (yes, no), baseline BMI, BMI change during follow-up, and passive smoking exposure in childhood and adulthood. Figure S2. Association of smoking cessation with non-fatal CVD events and CVD mortality among participants with and without diabetes. Number of participants included in the analysis: 6,049 former smokers and 19,397 current smokers. HRs (95% CIs) and P value were adjusted for age, sex, education attainment (less than high school, high school or further education), family history of diabetes (yes, no), family history of CVD (yes, no), fruits and vegetables intake (<4.5 cup/day, ≥4.5 cup/day), physical activity (active, insufficiently active, inactive), alcohol consumption, hypertension (yes, no), dyslipidemia (yes, no), baseline BMI, BMI change during follow-up, and passive smoking exposure in childhood and adulthood.

Acknowledgements
The authors thank all the study participants and research staff involved in the China Cardiometabolic Disease and Cancer Cohort Study and the members of the endocrinology department to Ruijin hospital for their support.

Authors’ contributions
YY, NP, QZ, and LS conceived and designed the study. All authors contributed to the acquisition or interpretation of the data. YY drafted the manuscript. NP conducted the analyses. YY, NP, and TW contributed to the statistical analysis. All authors contributed to the interpretation of the results and critical revision of the manuscript for important intellectual content. QZ, LS, WW, and GN contributed to funding acquisition. QZ and LS contributed to supervision and had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors approved the final version of the manuscript.

Funding
The 4C study was funded by Shanghai Key Laboratory for Endocrine Tumors, National Key R&D Program of China (2016YFC1305600, 2016YFC1305202, 2016YFC1304904, 2017YFC1310700, 2017YFC1309804, 2017YFC1309805, 2018YFC1311705, and 2018YFC1311800). This work was also funded by the Special Precision Medicine Project of the National Key R&D Program from the Science and Technology Ministry China(2016YFC0901020), Special Scientific Research Fund of Public Welfare Profession from the National Health and Family Planning Commission of PRC (201502007), and Key Clinical Specialty Cultivation Project of Guizhou Province (SZD-2016-01).

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethical approval and consent to participate
This study was approved by the Medical Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University. All study participants provided written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Endocrinology and Metabolism, Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, China. 2Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China. 3The Affiliated Hospital of Luzhou Medical College, Luzhou, China. 4Sun Yat-Sen Memorial Hospital, Guangzhou, China. 5The First Hospital of Jinlin University, Changchun, China. 6The First Affiliated Hospital of Guangxi Medical University, Nanning, China. 7The First Hospital of Lanzhou University, Lanzhou, China. 8Jiayi Provincial People’s Hospital Affiliated To Nanchang University, Nanchang, China. 9Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China. 10Division of Endocrinology, Department of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. 11Dalian Municipal Central Hospital, Dalian, China. 12Xinhu Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. 13Chinese People’s Liberation Army General Hospital, Beijing, China. 14Shandong Provincial Hospital Affiliated To Shandong University, Jinan, China. 15Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 16Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 17The Second Affiliated Hospital of Harbin Medical University, Harbin, China. 18The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. 19Qilu Hospital of Shandong University, Jinan, China. 20Central Hospital of Shanghai Jiaoding District, Shanghai, China. 21The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Medical University, Hefei, China. 22 The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 23 Jansu Province Hospital On Integration of Chinese and Western Medicine, Nanjing, China. 24 Karamay Municipal Medical University, Hefei, China. 22 The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 23 Jiangsu Province Hospital On Integration of Chinese and Western Medicine, Nanjing, China. 25 Department of Endocrinology and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 26 Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 28 Department of Endocrinology and Metabolism, GuOQian International General Hospital, Guiyang, China.

References

1. GBD 2015 Tobacco Collaborators. Tobacco Collaborators (2017) Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;389(10082):1885–906.

2. Barua RS, Rigotti NA, Benowitz NL, Cummings KM, Jazayeri MA, Morris PB, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the american college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol. 2018;72(25):3332–65.

3. Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10124):1145–58.

4. Hackshaw A, Morris JK, Boniface S, Tang JL, Milenkovic D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ. 2018;360:j5855.

5. Duncan MS, Freiberg MS, Grewey RA Jr, Kundu S, Vaian RS, Tindle HA. Association of smoking cessation with subsequent risk of cardiovascular disease. JAMA. 2019;322(7):642–50.

6. Pan A, Wang Y, Talaei M, Hu FB. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation. 2015;132(19):1795–804.

7. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Kondapally Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.

8. Rao Kondapally Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting glucose concentration, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10124):1145–58.

9. Hackshaw A, Morris JK, Boniface S, Tang JL, Milenkovic D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ. 2018;360:j5855.

10. Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS. Association of smoking cessation with subsequent risk of cardiovascular disease. JAMA. 2019;322(7):642–50.

11. Pan A, Wang Y, Talaei M, Hu FB. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation. 2015;132(19):1795–804.

12. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Kondapally Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.

13. Rao Kondapally Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting glucose concentration, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10124):1145–58.

14. Hackshaw A, Morris JK, Boniface S, Tang JL, Milenkovic D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ. 2018;360:j5855.

15. Duncan MS, Freiberg MS, Grewey RA Jr, Kundu S, Vaian RS, Tindle HA. Association of smoking cessation with subsequent risk of cardiovascular disease. JAMA. 2019;322(7):642–50.

16. Wang T, Lu J, Su Q, Chen Y, Li Y, Mu Y, et al. Ideal cardiovascular health metrics and major cardiovascular events in patients with prediabetes and diabetes. JAMA Cardiol. 2019;4(9):874–83.

17. Wang T, Lu J, Shi L, Chen G, Xu M, Xu Y, et al. Association of insulin resistance and B-cell dysfunction with incident diabetes among adults in China: a nationwide, population-based, prospective cohort study. Lancet Diabetes Endocrinol. 2020;8(2):115–24.

18. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381–95.

19. Ainsworth BE, Haskell WL, Leon AS, Jacobs DR, Montoye HJ, Sallis JF, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc. 1993;25(1):71–80.

20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.

21. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

22. Song YM, Cho HJ. Risk of stroke and myocardial infarction after reduction or cessation of cigarette smoking: a cohort study in korean men. Stroke. 2008;39(9):2432–8.

23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62–9.

24. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Horn LV, et al. American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586–613.

25. Lear SA, Hu W, Rangarajan S, Gasevic D, Leong D, Iqbal R, et al. The effect of physical activity on mortality and cardiovascular disease in 130000 people from 17 high-income, middle-income, and low-income countries: the PURE study. Lancet. 2017;390(10113):2643–54.

26. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(suppl1):S55–64.

27. Tian J, Sheng C, Sun W, Song X, Wang H, Li Q, et al. Effects of high blood pressure on cardiovascular disease events among chinese adults with different glucose metabolism. Diabetes Care. 2018;41(9):1895–900.

28. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/ABC/APA/ACPM/AGS/APha/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(10):e426–83.

29. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S125–50.

30. He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease—a meta-analysis of epidemiologic studies. N Engl J Med. 2011;364(9):829–41.

31. Eze IC, Schaffner E, Zemp E, Eckardstein A, Turk A, Bertschat R, et al. Environmental tobacco smoke exposure and diabetes in adult never-smokers. Environ Health. 2014;13(1):74–82.

32. Khoramdad M, Vaheidian-Azimi A, Karimi L, Rahimi-Bashar F, Amini H, Sahhekar A. Association between passive smoking and cardiovascular disease: a systematic review and meta-analysis. IUBMB Life. 2020;72(11):677–86.

33. Connor Gorber S, Schofield-Hurwitz S, Hardy J, Levasseur G, Tremblay M. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine Tob Res. 2009;11(1):12–24.

34. Al-Delaimy WK, Manson JE, Solomon CG, Kawachi I, Stampfer MJ, Willett WC, Hu FB. Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch Intern Med. 2002;162(3):273–9.

35. Fagard RH. Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. Diabetes Care. 2009;32(Suppl 2):S429–31.
36. Vazquez-Benitez G, Desai JR, Xu S, Goodrich GK, Schroeder EB, Nichols GA, et al. Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis. Diabetes Care. 2015;38(5):905–12.
37. Liu G, Li Y, Hu Y, Zong G, Li S, Rimm EB, et al. Influence of lifestyle on incident cardiovascular disease and mortality in patients with diabetes mellitus. J Am Coll Cardiol. 2018;71(25):2867–76.
38. Rawshani A, Rawshani A, Frantzén S, Sattar N, Eliasson B, Svensson A, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44.
39. Niemann B, Rohrbach S, Miller MR, Newby DE, Fuster V, Kovacic JC. Oxidative stress and cardiovascular risk: obesity, diabetes, smoking, and pollution: part 3 of a 3-part series. J Am Coll Cardiol. 2017;70(7):230–51.
40. Rigotti NA, Clair C. Managing tobacco use: the neglected cardiovascular disease risk factor. Eur Heart J. 2013;34(42):3259–67.
41. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140(11):e596–646.
42. Liu S, Zhang M, Yang L, Li Y, Wang L, Huang Z, et al. Prevalence and patterns of tobacco smoking among Chinese adult men and women: findings of the 2010 national smoking survey. J Epidemiol Community Health. 2017;71(2):154–61.
43. Xu Y, Wang L, He L, et al. 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948–59.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.